Breast cancer-directed gene delivery by AAV capsids displaying ESGLSQS depends on the underlying capsid serotype.

<p><b>A:</b> Luciferase activities in PymT-induced breast cancer tissue were determined as relative light units (RLU) per mg protein 14 days after injection of AAV2, -8 and -9 displaying breast cancer-directed peptides (ESGLSQS) or respective wild type capsid variants (n = 3). <b>B and C:</b> the amount of vector genomes recovered in tumor, liver and cardiac tissue was analyzed by quantitative real-time PCR using the tissue samples as described in A (n = 3 animals per group). <b>B:</b> ratio of vector genome copy numbers tumor/liver (n = 3 animals per group); <b>C:</b> ratio of vector genome copy numbers tumor/heart. <b>D and E:</b> ratios of gene transduction using AAV vectors of serotypes 2, 8 and 9 with insertion of the ESGLSQS peptide and respective wild type variants. Values were calculated as <b>D:</b> tumor/liver expression ratios or <b>E:</b> tumor/heart expression ratios, respectively. <b>F, G and H:</b> Luciferase activities in various tissues were detected as relative light units (RLU) per mg protein for AAV-2 (<b>F</b>) for AAV-8 (<b>G</b>) and AAV-9 (<b>H</b>) displaying breast cancer-directed peptides (ESGLSQS) or respective AAV wild type capsid variants (n = 3 animals per group).